What Aura Biosciences does

Aura Biosciences is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, that is developing a new class of targeted cancer therapeutics called Virus-Like Drug Conjugates (VDCs). The proprietary platform is built on HPV-derived virus-like particles (VLPs) conjugated with a light-activated cytotoxin; VDCs selectively bind a unique sulfation pattern in modified tumor-associated glycosaminoglycans (GAGs) that is not present on normal cells, enabling a dual mechanism of action consisting of acute necrosis via singlet oxygen generation upon infrared light activation plus a secondary immune-mediated antitumor response. The company's sole clinical asset is belzupacap sarotalocan (bel-sar, also known as AU-011), a first-in-class VDC being developed across four programs: lead Phase 3 CoMpass trial in early choroidal melanoma (108 patients enrolled, topline data H2 2027), choroidal metastasis, non-muscle invasive bladder cancer (FDA Fast Track), and an exploratory systemic solid tumor program.

Aura operates under a standard clinical-stage biotech business model with no marketed products and no product revenue. The lead candidate's commercial opportunity targets a small, concentrated prescriber base of approximately 100 ocular oncology specialists across the US and EU5 treating a US/EU addressable population of roughly 9,000 early-stage choroidal melanoma patients annually; broader urologic and solid tumor indications could substantially expand the addressable market. Aura has executed multiple dilutive public equity offerings since its 2021 NASDAQ IPO, raising over $559 million cumulatively, and held $144.2 million in cash and marketable securities as of Q4 2025 (supplemented by a $299.4M May 2026 raise) to fund operations through and beyond Phase 3 readout. The company monetizes through future drug product sales contingent on regulatory approval, with no current pricing disclosed, and currently relies on scientific conferences, peer-reviewed publications, and investor relations as its primary go-to-market channels during the clinical phase.

Name

Aura Biosciences

Legal name

Aura Biosciences, Inc.

Website

https://aurabiosciences.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

101–250 employees

Short description

Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugate (VDC) therapies, with lead candidate bel-sar in a Phase 3 trial for early choroidal melanoma and additional programs in bladder cancer and other solid tumors, targeting rare ocular and urologic oncology indications with no approved drug therapies.

Ownership category

akta.pro rank

Product category

Ocular Oncology Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

akta.pro secondary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

Keywords

• Virus-like drug conjugates
• Ocular oncology therapeutics
• Targeted cancer biologics
• Urologic oncology treatment
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pre-revenue / Future drug product sales: Aura is a clinical-stage biotechnology company currently developing virus-like drug conjugate (VDC) therapeutics with no marketed products. Future revenue is expected to come from sales of its lead candidate bel-sar (AU-011) and follow-on VDC products upon regulatory approval in ocular and urologic oncology indications.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels6 records

Core offering

Aura Biosciences develops a proprietary Virus-Like Drug Conjugate (VDC) platform that uses HPV-derived virus-like particles conjugated with a light-activated cytotoxin to selectively target cancer cells through binding modified tumor-associated glycosaminoglycans (GAGs). Its lead clinical-stage candidate, belzupacap sarotalocan (bel-sar/AU-011), is currently in a global Phase 3 trial (CoMpass) for first-line treatment of early choroidal melanoma, with additional programs in choroidal metastasis, non-muscle invasive bladder cancer, muscle invasive bladder cancer, and other solid tumors.

Product overview

Aura Biosciences offers a single, integrated precision oncology platform anchored by its proprietary Virus-Like Drug Conjugate (VDC) technology and a single lead clinical-stage asset, belzupacap sarotalocan (bel-sar, also known as AU-011). The VDC Platform is the core technology; built on HPV-derived virus-like particles conjugated with cytotoxic drugs, it enables targeted delivery to tumors expressing modified glycosaminoglycans (GAGs). This platform powers a modular pipeline of indication programs sharing the same drug substance: the lead Choroidal Melanoma Program (currently in the registrational Phase 3 CoMpass trial), the Choroidal Metastasis Program, the Bladder Cancer Program (NMIBC and MIBC), and an exploratory Other Solid Tumors Program covering lung, ovarian, prostate, colon, and other solid tumors. Together, the VDC Platform and bel-sar–derived indication programs form Aura's portfolio focused initially on ocular and urologic oncology.

Differentiator

Problem solved

Functional benefit

Products and services

• Virus-Like Drug Conjugate (VDC) Platform Aura's proprietary targeted oncology platform that uses virus-like particles (VLPs) derived from human papillomavirus (HPV) conjugated with light-activated cytotoxic drugs to create a new class of targeted cancer therapies. VLPs selectively bind modified tumor-associated glycosaminoglycans (GAGs) on cancer cells, enabling delivery of hundreds of cytotoxic molecules per capsid with a dual mechanism of action (acute photodynamic necrosis plus immune-mediated antitumor response).
• Belzupacap Sarotalocan (bel-sar / AU-011) Lead clinical-stage VDC candidate built on the Aura platform. A virus-like particle conjugated with a novel light-activated cytotoxin being developed as a first-line, vision-preserving therapy for early-stage choroidal melanoma (Phase 3 CoMpass trial; enrollment of 108 patients completed, topline data expected H2 2027), with additional programs in choroidal metastasis, non-muscle invasive and muscle invasive bladder cancer, and other solid tumors.
• Ocular Oncology Program Therapeutic program addressing a group of rare, life-threatening ocular cancers including choroidal melanoma, choroidal metastasis, cancers of the ocular surface, and retinoblastoma, with bel-sar as the lead candidate. Treated by approximately 100 ocular oncology specialists in the US and EU.
• Choroidal Melanoma Program (bel-sar) Lead indication program for bel-sar targeting early-stage choroidal melanoma (small melanomas and indeterminate lesions), representing approximately 9,000 addressable patients in the United States and Europe. There are no FDA-approved drug therapies for choroidal melanoma. The global Phase 3 CoMpass trial has completed enrollment with 108 patients.
• Choroidal Metastasis Program (bel-sar) Program evaluating bel-sar for the most common intraocular malignancy, choroidal metastasis, caused by metastases from primary breast, lung, gastrointestinal, prostate, skin melanoma, and kidney tumors. Bel-sar's GAG-targeting mechanism is mutation-agnostic, making it applicable across multiple primary tumor types.
• Bladder Cancer Program (bel-sar) First non-ocular solid tumor program for bel-sar, targeting non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC), with a yearly US incidence of 81,000 patients. Fast Track Designation received from the FDA; Phase 1b/2 NMIBC trial ongoing with initial 3-month data expected in mid-2026.
• Other Solid Tumors Program Exploratory program leveraging the VDC platform's broad tropism for modified tumor-associated GAGs on solid tumors, with preclinical data showing picomolar in vitro activity and dose-dependent durable tumor regressions after single systemic administration of bel-sar in xenograft models of lung, ovarian, bladder, melanoma, prostate, and colon cancers. A new formulation with 12-month stability has been achieved for non-ocular solid tumors, beginning with urologic oncology.

Quantifiable outcome

• 11,000 new choroidal melanoma patients per year in the US and Europe
• +5 more outcomes

Named customers1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor and core.

• Melanoma Research FoundationminorGTM or Marketing Partner · 16 May 2026Aura Biosciences participated as a supporting sponsor of the Melanoma Research Foundation's annual Miles for Melanoma 5K event scheduled for May 16, 2026 at Franklin Park Zoo in Boston, alongside Pfizer, Bristol Myers Squibb, Natera, Replimune, and Castle Biosciences, with a $150,000 fundraising goal to support melanoma research, education, and advocacy.
• John T. Schiller, PhDcoreOthersJohn T. Schiller, PhD serves as Scientific Founder of Aura Biosciences. He is Deputy Chief and Head of the Neoplastic Disease Section, Laboratory of Cellular Oncology at the National Cancer Institute, NIH, and an NIH Distinguished Investigator. He received the Lasker DeBakey Award in 2017 and the National Medal of Technology and Innovation in 2014 for his work on HPV vaccine development, providing the foundational HPV science underlying the VLP/VDC platform.

Scale indicators16 records

Recent moves10 records

Expansion highlights6 records

Direct peers

• Immunocore Holdings: Immunocore commercializes tebentafusp (Kimmtrak) for HLA-A*02:01-positive metastatic uveal melanoma, making it the closest direct peer in ocular/uveal melanoma. Both companies target melanomas of the eye with novel biologic platforms, although Immunocore uses a TCR-based mechanism and Aura uses VDCs.
• Replimune Group: Replimune develops an oncolytic immunotherapy platform (RP1/RP2/RP3) for solid tumors including cutaneous melanoma. As a virus-derived oncology platform with clinical assets across multiple tumor types, it is highly comparable to Aura's virus-like drug conjugate technology in mechanism philosophy and indication breadth.
• Castle Biosciences: Castle Biosciences' DecisionDx product line includes uveal melanoma prognostic testing, directly addressing the same patient population as Aura's choroidal melanoma program. They operate in the ocular oncology commercial ecosystem and have been co-marketed alongside Aura at melanoma awareness events.
• CG Oncology (formerly Cold Genesys): CG Oncology is a late-stage biotech developing nadofaragene firadenovec for non-muscle invasive bladder cancer (NMIBC), a direct competitor to Aura's bel-sar NMIBC program. Both companies are pursuing novel intravesical biologic therapies for the same bladder cancer indication.

Broad incumbents

• ADC Therapeutics: ADC Therapeutics is a clinical-to-commercial stage company commercializing ADCs (antibody-drug conjugates) for hematologic and solid tumors. Aura's VDC platform is the virus-based analogue of ADCs, and the two represent alternative targeted-conjugate paradigms for oncology drug development.
• Iovance Biotherapeutics: Iovance is a commercial-stage cell therapy company with approved TIL therapies for advanced melanoma. As a fellow NASDAQ-listed late-stage/early-commercial oncology company focused on melanoma indications, Iovance provides a relevant valuation and trajectory benchmark for Aura's pre-launch phase.

Emerging players

• Bolt Biotherapeutics: Bolt Biotherapeutics develops immune-stimulating antibody conjugates (ISACs) that combine tumor-targeted delivery with immune activation — conceptually analogous to Aura's VDCs that combine targeted delivery with dual necrosis + immune response. Both are clinical-stage platforms pairing targeted payloads with immune-mediated antitumor effects.
• Mersana Therapeutics: Mersana is a clinical-stage biotech developing next-generation ADCs with proprietary payload and linker chemistries for solid tumors. As a platform-based targeted oncology company with multiple clinical assets, Mersana is comparable to Aura in stage, business model, and clinical risk profile.
• Pyxis Oncology: Pyxis Oncology is a clinical-stage oncology company developing antibody-drug conjugates and immune-engaging therapeutics for solid tumors. Like Aura, Pyxis is building a multi-asset targeted oncology pipeline from a single technology platform.
• IDEAYA Biosciences: IDEAYA is a clinical-stage precision medicine oncology company developing targeted therapies across multiple solid tumor indications. Both IDEAYA and Aura are small-cap, multi-indication, biomarker-driven oncology platforms advancing from rare to larger solid tumor markets.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/aurabiosciences
• LinkedInlinkedin.com/company/aurabiosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds16 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aura Biosciences